ANALYZE — plain-language breakdown + contested concern
Gold standard (ADA 2026): Scheduled insulin (basal + prandial bolus + correction) is the preferred treatment for most noncritically ill hospitalized patients with diabetes and adequate nutritional intake.
When to start scheduled insulin: Persistent hyperglycemia = ≥2 glucose readings >180 mg/dL in 24h.
Target: 140–180 mg/dL for non-ICU (tighter in select populations).
What NOT to do: Prolonged use of correction/sliding-scale insulin alone (no basal) is strongly discouraged except for:
- T2D in non-critical care with mild hyperglycemia (staying <180 mg/dL)
- Stress hyperglycemia maintaining <180 mg/dL
Proven superiority: RCT showed basal-bolus improved glycemic outcomes + reduced hospital complications vs correction-only insulin in T2D general surgery patients.
Real-world gap (Frontiers 2024): Community hospitals still use correction-only more than they should — the basal-bolus evidence base is strong, but workflow/nursing comfort barriers persist.
At the bedside / For clinical AI
✅ Implementable protocol:
- Trigger: 2+ BG readings >180 in 24h → auto-flag for scheduled insulin
- Order set: basal (glargine/detemir QD or NPH BID) + prandial (lispro/aspart AC) + correction scale
- Dose calc: 0.3–0.5 units/kg/day total daily dose (50% basal, 50% prandial split across meals)
- Adjust daily based on patterns (not just correction doses)
⚖️ Contested / emerging: Can DPP-4 inhibitors (sitagliptin) safely reduce insulin requirements in non-diabetic patients on high-dose steroids? (Clinical trial data emerging, not yet standard-of-care.)
🟡 Workflow barrier: Many floor nurses are more comfortable with correction scales than basal-bolus titration. Fix: pharmacist-driven insulin dosing service (shown to improve outcomes in several health systems).
Sources
- ADA Standards of Care 2026
- Glytec 2025
- Diabetes Care 2025
- Cleveland Clinic J Med 2023
- Frontiers J Pharm Sci 2024
— Jeremy Tabernero, MD · More literature watch · Get in touch